Piramal Pharma cutting China exposure to manage supply-chain resilience, says Nandini Piramal

In a strategic move to enhance risk management, Piramal Pharma has drastically cut its reliance on Chinese raw materials to under 10%. The company is actively diversifying its supply chains to provide greater flexibility against geopolitical challenges while broadening its manufacturing footprint to locations like India, the UK, and the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LhrKOSZ
via IFTTT